Aligos Therapeutics
ALGS
51 hedge funds and large institutions have $749M invested in Aligos Therapeutics in 2020 Q4 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.86% more ownership
Funds ownership: 0% → 2.86% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$76.5M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$69.1M |
| 3 |
VVM
Versant Venture Management
San Francisco,
California
|
+$64.1M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$50.9M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$42.2M |
Top Sellers
ALGS Hedge Fund Activity: Q4 2020 in Review
51 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q4 2020, worth a combined $749M.
Buyers outnumbered sellers: 51 funds opened new ALGS positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $76.5M.
- 51 institutional investors held Aligos Therapeutics (ALGS) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $749M of Aligos Therapeutics stock for Q4 2020.
- 51 funds opened new Aligos Therapeutics positions in Q4 2020 and 0 closed out, a net change of +51 holders.
- The largest Aligos Therapeutics buyer in Q4 2020 was Wellington Management Group, an estimated $76.5M added.
Based on aggregated 13F filings for Q4 2020.